

## Jentaducto - (2.5 mg/ 500,850,1000mg; Tablet, Oral)

|                              |  |                             |                      |
|------------------------------|--|-----------------------------|----------------------|
| <b>Generic Name</b>          | Linagliptin and Metformin Hydrochloride  | <b>Innovator</b>            | Boehringer Ingelheim |
| <b>Dosage</b>                | 2.5 mg/ 500,850,1000mg; Tablet, Oral   | <b>Branded US Sales</b>     | Less Than \$1000 mn  |
| <b>Probable FTF</b>          | More Than 5  | <b>Known Para IV Filers</b> | More Than 5          |
| <b>Other ANDA developers</b> | More Than 5  | <b>Tentative Approvals</b>  | Less Than 5          |
| <b>Final Approvals</b>       | Less Than 5  | <b>Generic Launches</b>     | None                 |
| <b>Indication</b>            | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate |                             |                      |
| <b>Complexities</b>          | Yes  |                             |                      |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.